Blood cancers

A haematologist’s experience of ruxolitinib in Intermediate-1 myelofibrosis patients

Sponsored by Novartis Oncology

The selective Janus kinase (JAK) 1 and JAK2 inhibitor ruxolitinib was approved by the PBS in February for use in patients with myelofibrosis1 Dr Lynette Chee, a consultant haematologist at the Royal Melbourne Hospital, describes its use in a 43-year-old woman with Intermediate-1 risk myelofibrosis. She also outlines the evidence around the drug and gives ...

Already a member?

Login to keep reading.

© 2021 the limbic